News

GC Biopharma Presents New Viscosity Research on IVIG Products at ISTH 2025
GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data on the viscosity of several commercially available 10% intravenous immunoglobulin (IVIG) products at ...
Physician's Weekly2d
Atypical GBS Recurrence Involves Nausea, Vomiting as Sole Symptoms
A rare Guillain-Barré syndrome recurrence caused nausea with no motor symptoms but was treated successfully with intravenous ...
Annexon: Lead GBS Therapy Stokes Near-Term Potential
Annexon offers speculative upside with Tanruprubart, targeting Guillain-Barré Syndrome's unmet needs. Click here to read my ...
Advertiser and Times5d
Darren Hodson will be at The Barn in Ringwood with his tribute to country singer Chris Stapleton
Darren’s life changed overnight when he was temporarily paralysed by the rare neurological disorder Guillain-Barré syndrome ...
Targeted Oncology6d
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...
Idiopathic Thrombocytopenic Purpura Market Set for Robust Growth Through 2032, Driven by Emerging Therapies and Strategic Collaborations | DelveInsight
The Idiopathic Thrombocytopenic Purpura market is poised for significant expansion through 2032, underpinned by rising disease awareness, improving epidemiological understanding, and a vibrant ...
Targeted Oncology8d
Newer Approaches Show Potential to Reduce Need for Transplant in NDMM
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...
AGDAILY8d
EEEV increase in the U.S. poses risks to humans and horses
A new JAMA report warns of rising eastern Equine encephalitis cases in the U.S., giving attention to neurological impacts in ...
Finanznachrichten8d
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016 ® [Vaccinia Immune Globulin ...
The Bakersfield Californian9d
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia ...
Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) ...
Infectious Disease Advisor10d
Ready-To-Use, Low IgA Gammagard Liquid ERC Approved for Primary Immunodeficiency
The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.
Man, 24, breaks out in horror rash and risks bleeding to death after taking petrol station ‘Viagra’
A YOUNG man faced the terrifying risk of internal bleeding after taking a ‘Viagra’ pill bought from a petrol station. The 24-year-old ended up in a US hospital after developing unusual ...